Should I Buy BBNX? BBNX 2026 Analysis

Should You Buy Beta Bionics Inc (BBNX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

13.080

1 Day change

-1.21%

52 Week Range

32.710

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: trend is still bearish (SMA200 > SMA20 > SMA5) and price is below the pivot (15.639), so rallies are likely to face overhead supply.
No Intellectia edge today: AI Stock Picker = no signal; SwingMax = no recent signal, so there’s no proprietary “must-buy-now” trigger.
Risk/reward is mixed near support: pre-market ~14.48 is closer to S1 (13.718) than to upside resistance (17.561), meaning downside to support is relatively near if selling resumes.
Best stance: HOLD (avoid new buys until price reclaims ~15.64 pivot and/or earnings (2026-02-17) clears uncertainty).

Technical Analysis

Trend: Bearish alignment (SMA_200 > SMA_20 > SMA_5) suggests the primary trend is down.
Momentum: MACD histogram -0.128 is below zero but negatively contracting → selling pressure may be easing, allowing short-term bounces, but not yet a confirmed reversal.
RSI: RSI_6 at 28.742 indicates the stock is stretched to the downside (oversold/near-oversold), which can fuel a reflex rally, but oversold alone is not a buy signal in a downtrend.
Key levels: Pivot 15.639 (must reclaim for bullish shift); Support S1 13.718 then S2 12.531; Resistance R1 17.561 then R2 18.748.
Pattern-based forward look: Similar-pattern stats imply ~5.26% upside bias over the next month, but near-flat expected next day/week—supports “wait for confirmation” rather than chase now.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Volatility: Implied vol (30D) ~114% vs historical vol ~33% → options are priced for large moves; sentiment is “uncertainty/high event risk.”
Liquidity/positioning: Extremely light OI/volume (call OI 0, put OI 1; today volume 4 puts, 0 calls) → the put/call ratios read as 0.0 largely due to sparse data, so don’t over-interpret sentiment from PCR.
Takeaway: Options market is signaling big-move risk (high IV) but not providing a reliable directional read due to very low participation.

Technical Summary

Sell

Buy

Positive Catalysts

and Truist still Buy despite PT cut; “buy weakness” framing can support dips if fundamentals hold.

Neutral/Negative Catalysts

is reclaimed, downside tests of 13.718/12.531 remain plausible.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $27.253M, +63.14% YoY (strong top-line growth).
Profitability trend: Net income -$14.209M, improved 45.94% YoY (loss narrowing).
EPS: -0.33, improved 43.48% YoY.
Margins: Gross margin 55.48%, +3.97% YoY (favorable unit economics trend).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent tone has shifted more cautious despite some remaining Buys.
2026-02-02 Truist: PT cut to $25 from $37, kept Buy (FDA Warning Letter headline weighs on sentiment).
2026-01-26 TD Cowen: initiated Hold, PT $17 (expects continued revenue upside, but not enough for an outsized multiple).
2026-01-09 BofA: downgraded to Neutral from Buy, PT $28 (new patient starts missed expectations; valuation concern).
2026-01-09 Lake Street: reiterated Buy, raised PT to $40 (buyers of weakness; sees continued execution/product catalysts).
2025-12-16 Baird: Neutral, PT $28.
Wall Street pros/cons summary: Pros = strong growth and improving margins with product differentiation; Cons = demand growth deceleration signals, regulatory/legal headline risk, and reduced willingness to award a premium multiple right now.

7 Analyst Rating

Wall Street analysts forecast BBNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBNX is 32 USD with a low forecast of 28 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 13.240

Low

Averages

High

Current: 13.240

Low

Averages

High

Stifel

Buy

downgrade

$31 -> $25

AI Analysis

2026-02-04

New

Reason

Stifel

Price Target

$31 -> $25

AI Analysis

2026-02-04

New

downgrade

Buy

Reason

Stifel lowered the firm's price target on Beta Bionics to $25 from $31 and keeps a Buy rating on the shares as part of the firm's 2026 overview note for the dental, diabetes, and aesthetics sectors.

Truist

Buy

downgrade

$37 -> $25

2026-02-02

New

Reason

Truist

Price Target

$37 -> $25

2026-02-02

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Beta Bionics to $25 from $37 but keeps a Buy rating on the shares after the company disclosed FDA Warning Letter on Friday related to "deficiencies in responses" to the FDA's Form 483. The operational risk will be minimal, though this is still a negative headline at a time the diabetes sector is out-of-favor and Beta Bionics specifically is "on its heels" after its negative Q4 pre-announcement, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBNX

Unlock Now

BBNX Should I Buy

BBNX Should I Buy

Should You Buy Beta Bionics Inc (BBNX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch